Article
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2025 Update.
Clinical pharmacology and therapeutics - 1 Apr 2026
Maillard Maud, Schwab Matthias, Whirl-Carrillo Michelle, Moyer Ann M, Suarez-Kurtz Guilherme, Pui Ching-Hon, Stein C Michael, Klein Teri E, Spahn Claire, Kwon Sooyeon, Hartono Juanda Leo, de Boer Nanne K, Ahmad Tariq, Antillon-Klussmann Federico Guillermo, Caudle Kelly E, Kato Motohiro, Yeoh Allen E J, Schmiegelow Kjeld, Yang Jun J
Abstract excerpt
Thiopurine methyltransferase (TPMT) and Nudix hydrolase 15 (NUDT15) are key enzymes that catabolize thiopurines. Decreased or no-function alleles in TPMT and NUDT15 are associated with reduced or no enzyme activity and predictive of pronounced adverse effects, including severe myelosuppression, that may occur among individuals treated with standard doses of thiopurines. Genetic variants in these genes are present...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
